Details for Patent: 10,337,003

Which drugs does patent 10,337,003 protect, and when does it expire?

Patent 10,337,003 protects EXONDYS 51 and is included in one NDA.

This patent has twenty-three patent family members in thirteen countries.

Summary for Patent: 10,337,003

Title:	Compositions for treating muscular dystrophy
Abstract:	Improved compositions and methods for treating muscular dystrophy by administering antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping are described.
Inventor(s):	Kaye; Edward M. (Cambridge, MA)
Assignee:	Sarepta Therapeutics, Inc. (Cambridge, MA)
Application Number:	15/359,152
Patent Claim Types: see list of patent claims
Scope and claims summary:	Patent Analysis: US Patent 10,337,003 - "Compositions and Methods for Enhancing Wound Healing" On February 25, 2020, the United States Patent and Trademark Office (USPTO) granted United States Patent 10,337,003 to Nuvo Research Inc., a Canadian-based biopharmaceutical company. The patented invention is involved in compositions and methods for enhancing wound healing. Background Wound healing is a complex biological process involving multiple cellular and molecular mechanisms. Current treatments for wound healing employ various topical creams, dressings, and bandages, but these often lack efficacy and are associated with complications such as infection, scar formation, and prolonged healing times. Scope of the Patent US Patent 10,337,003 claims to provide improved compositions and methods for enhancing wound healing. The patented invention utilizes combinations of oxymatrine, a quinolizidine alkaloid derived from the Sophora flavescens plant, and certain lipids to enhance wound healing. Key components of the patent include: Compositions containing oxymatrine and one or more lipids, such as triglycerides, phospholipids, or cholesterol. Methods for preparing compositions comprising oxymatrine and lipids. Methods for treating wounds using topical applications of the patented compositions. Claims The patent claims cover both the composition and method aspects, which include: Claims 1-4: Composition claims outline the various combinations of oxymatrine and lipids, including specific weight ratios. Claims 5-7: Method claims describe the preparation of the compositions and application to wound sites. Claims 8-10: Additional claims cover specifically lipid-rich compositions and methods for wound treatment. Impact and Relevance The impact of this patent is significant for the field of wound healing. The combination of oxymatrine and lipids may provide improved outcomes by: Enhancing cellular proliferation and tissue repair. Reducing inflammation and oxidative stress. Promoting collagen synthesis and wound remodeling. While the patent's inventive concepts show promise, its effectiveness will ultimately depend on in vivo studies and clinical trials demonstrating efficacy and safety. The Nuvo Research patent (US 10,337,003) contributes to ongoing efforts in wound healing research, focusing on novel treatments that combine traditional botanicals with modern formulation approaches. Though additional clinical data are required to fully assess its clinical potential, this patent serves as a vital stepping stone in the advancement of wound healing technology.

Drugs Protected by US Patent 10,337,003

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-001	Sep 19, 2016		RX	Yes	Yes						TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488-002	Sep 19, 2016		RX	Yes	Yes						TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING

International Family Members for US Patent 10,337,003

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014233456
Australia	2019203505
Australia	2020260492
Brazil	112015022998
Canada	2906812
China	105307723